SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-23-026139
Filing Date
2023-02-27
Accepted
2023-02-27 18:08:34
Documents
1
Period of Report
2023-02-24

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm237991-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm237991-1_4seq1.xml 4 3616
  Complete submission text file 0001104659-23-026139.txt   5113
Mailing Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035
Business Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035 617-679-9600
Rubius Therapeutics, Inc. (Issuer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O RUBIUS THERAPEUTICS, INC. 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address
Appelhans Dannielle (Reporting) CIK: 0001874962 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38586 | Film No.: 23677155